CR10251A - Compuestos de n-formil-hidroxilamina - Google Patents

Compuestos de n-formil-hidroxilamina

Info

Publication number
CR10251A
CR10251A CR10251A CR10251A CR10251A CR 10251 A CR10251 A CR 10251A CR 10251 A CR10251 A CR 10251A CR 10251 A CR10251 A CR 10251A CR 10251 A CR10251 A CR 10251A
Authority
CR
Costa Rica
Prior art keywords
compounds
formil
hydroxylamine compounds
formylhydroxylamine
disclosed
Prior art date
Application number
CR10251A
Other languages
English (en)
Inventor
Kwangho Lee
Jennifer Leeds
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of CR10251A publication Critical patent/CR10251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se dan a conocer novedosos compeustos de N-formilhidroxilamina y sus derivados. Estos compuestos de N-formilhidroxilamina inhiben la peptidil-desformilasa (PDF), una enzima presente en los procariotes. Los compuestos son útiles como antimicrobianos y antibióticos. Los compuestos de la invención exhiben una inhibición selectiva de la peptidil-desformilasa contra otras metaloproteinasas, tales como MMPs. También se dan a conocer métodos de preparación y uso de los compuestos.
CR10251A 2006-03-03 2008-08-26 Compuestos de n-formil-hidroxilamina CR10251A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77937706P 2006-03-03 2006-03-03

Publications (1)

Publication Number Publication Date
CR10251A true CR10251A (es) 2008-10-27

Family

ID=38510154

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10251A CR10251A (es) 2006-03-03 2008-08-26 Compuestos de n-formil-hidroxilamina

Country Status (19)

Country Link
US (1) US20090062537A1 (es)
EP (1) EP1994027A2 (es)
JP (1) JP2009529008A (es)
KR (1) KR20080095895A (es)
CN (1) CN101395148A (es)
AU (1) AU2007226715A1 (es)
BR (1) BRPI0708524A2 (es)
CA (1) CA2643267A1 (es)
CR (1) CR10251A (es)
EC (1) ECSP088712A (es)
GT (1) GT200800170A (es)
IL (1) IL193524A0 (es)
MA (1) MA30285B1 (es)
MX (1) MX2008011128A (es)
NO (1) NO20084069L (es)
RU (1) RU2008139192A (es)
TN (1) TNSN08344A1 (es)
WO (1) WO2007106670A2 (es)
ZA (1) ZA200807054B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101584694B (zh) * 2009-06-15 2011-01-12 华东师范大学 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法
CN101869563B (zh) * 2010-07-02 2011-11-16 华东师范大学 含4-亚甲基吡咯烷的肽脱甲酰基酶抑制剂
AR085698A1 (es) * 2011-03-09 2013-10-23 Glaxosmithkline Llc Inhibidores de la peptido desformilasa
CN103159660B (zh) * 2011-12-08 2016-07-06 天津市国际生物医药联合研究院 (2r)-1-(2-甲基-3-(甲氧基(甲基)氨基)-丙酰基)吡咯烷-2-羧酸及其应用
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
CN117736134A (zh) * 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
EP2817291A1 (en) 2012-02-24 2014-12-31 F. Hoffmann-La Roche AG Antiviral compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
RS65894B1 (sr) * 2014-02-06 2024-09-30 Nxera Pharma Uk Ltd Biciklična aza jedinjenja kao agonisti muskarinskog receptora
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN107428734A (zh) 2015-01-20 2017-12-01 阿尔维纳斯股份有限公司 用于雄激素受体的靶向降解的化合物和方法
CA2979070A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20180097530A (ko) 2015-11-02 2018-08-31 예일 유니버시티 단백질분해 표적화 키메라 화합물(Proteolysis Targeting Chimera compound) 및 그의 제조 및 사용 방법
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
KR102173463B1 (ko) 2016-10-11 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
CA3042260C (en) 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
JP2020504741A (ja) 2016-12-23 2020-02-13 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
EP3559002A4 (en) 2016-12-23 2021-02-17 Arvinas Operations, Inc. CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
WO2018140809A1 (en) 2017-01-26 2018-08-02 Arvinas, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
AU2019249231B2 (en) 2018-04-04 2022-04-21 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN118638043A (zh) 2019-12-19 2024-09-13 阿尔维纳斯运营股份有限公司 用于雄激素受体的靶向降解的化合物和方法
EP4146642A1 (en) 2020-05-09 2023-03-15 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
US11986532B2 (en) 2021-04-16 2024-05-21 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036053A1 (es) * 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
CN101092342A (zh) * 2003-02-21 2007-12-26 诺瓦提斯公司 制备用以获得n－甲酰基羟胺的中间体的化学方法

Also Published As

Publication number Publication date
IL193524A0 (en) 2009-08-03
MX2008011128A (es) 2008-09-08
WO2007106670A2 (en) 2007-09-20
RU2008139192A (ru) 2010-04-10
US20090062537A1 (en) 2009-03-05
ECSP088712A (es) 2008-10-31
CN101395148A (zh) 2009-03-25
ZA200807054B (en) 2009-10-28
NO20084069L (no) 2008-12-03
KR20080095895A (ko) 2008-10-29
JP2009529008A (ja) 2009-08-13
TNSN08344A1 (en) 2009-12-29
AU2007226715A1 (en) 2007-09-20
EP1994027A2 (en) 2008-11-26
WO2007106670A3 (en) 2008-01-24
GT200800170A (es) 2008-10-29
MA30285B1 (fr) 2009-03-02
CA2643267A1 (en) 2007-09-20
BRPI0708524A2 (pt) 2011-05-31

Similar Documents

Publication Publication Date Title
CR10251A (es) Compuestos de n-formil-hidroxilamina
AR056360A1 (es) Compuestos de n- formil- hidroxilamina
BRPI0717266A2 (pt) Derivados de oxindol
GT200600117A (es) Nuevos compuestos farmaceuticos
UA94412C2 (en) Glutamate aggrecanase inhibitors
UY30748A1 (es) Compuesto0s novedosos
WO2007077186A8 (en) Pdf inhibitors
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
BRPI0511133A (pt) uso de galacto-oligossacarìdeos e polifrutose
MX2009004766A (es) Derivados de espiroindolinona.
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
GT200900186A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
BR112013014119A8 (pt) Novos moduladores e métodos de uso
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
ECSP088558A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
BRPI0508894A (pt) meios para administração transdérmica de nicotina e uso
MX2013007236A (es) Composiciones fluidas que comprenden un agente de estructuracion.
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
EA201000070A1 (ru) Модуляторы калликреина 7
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
ATE528290T1 (de) Spiroindolinon-derivate
PA8792401A1 (es) Fenilendiaminas
TR200902923T2 (tr) Megestrol maddenin farmasötik olarak kararlı bir süspansiyonu.
GT201200017A (es) Preparacion de (r) y (s) - (3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino-6-metoxifenil)-1-(2,3-dihidroxipropil) ciclopropan-1-sulfonamida y derivados protegidos de los mismos: